Target Group and Market

Because RhoC is overexpressed at high concentrations in nearly all metastatic cancer cells, the product RhoVac is developing has the potential to treat a broad range of cancers.

In 2012, almost 14.1 million new cases of cancer were diagnosed throughout the world. About 58,000 people In Sweden became ill with cancer during 2013. The number of cancer cases is increasing continuously – since 1979 the number of cancer cases has doubled. This increase is explained by improved diagnostic methods and a longer-living population. Moreover, Western lifestyles that include smoking, alcohol consumption, unhealthy diets, little physical activity, being overweight/obese, and incorrect sunbathing habits have been shown to increase the risk of developing cancer. What is clear is that cancer affects huge numbers of people.

The RhoVac cancer vaccine product RV001 is designed to stimulate the immune system to target metastatic cancer cells, regardless of which type of cancer the patient may have. This means that when the company completes the planned clinical studies successfully, the market potential for RhoVac’s immunotherapy will be huge. To name only a few relevant indications – over 2 million new cases of lung cancer are found world-wide every year, more than 1 million new cases of prostate cancer arise every year, and over 1.5 million cases of breast cancer every year.